Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Buy
67
GPCR Quote, Financials, Valuation and Earnings
Last price:
$69.99
Seasonality move
:
-31.39%
Day range:
$44.74 - $94.90
52-week range:
$13.22 - $94.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.23x
Volume:
19.5M
Avg. volume:
1.8M
1-year change:
109.84%
Market cap:
$4B
Revenue:
--
EPS (TTM):
-$3.65
Analysts' Opinion
-
Consensus RatingStructure Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $76.36, Structure Therapeutics, Inc. has an estimated upside of 9.11% from its current price of $69.98.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $44.00 representing 37.13% downside risk from its current price of $69.98.
Fair Value
-
According to the consensus of 10 analysts, Structure Therapeutics, Inc. has 9.11% upside to fair value with a price target of $76.36 per share.
GPCR vs. S&P 500
-
Over the past 5 trading days, Structure Therapeutics, Inc. has overperformed the S&P 500 by 102.53% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Structure Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Structure Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Structure Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Structure Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Structure Therapeutics, Inc. reported earnings per share of -$1.13.
Enterprise value:
3.2B
EV / Invested capital:
4.17x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.30x
EV / Free cash flow:
-16.47x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$4.4M
Return On Assets:
-24.24%
Net Income Margin (TTM):
--
Return On Equity:
-25.55%
Return On Invested Capital:
-25.36%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$812.7K | -$1.4M | -$4.4M | -$267.2K | -$978.3K | |
| Operating Income | -$84.4M | -$142.7M | -$247.9M | -$46.2M | -$73.9M | |
| EBITDA | -$83.6M | -$141.2M | -$243.5M | -$45.9M | -$72.9M | |
| Diluted EPS | -$2.30 | -$2.21 | -$3.65 | -$0.60 | -$1.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $210M | $923.7M | $814M | |
| Total Assets | -- | -- | $216.4M | $933.2M | $832.2M | |
| Current Liabilities | -- | -- | $20.1M | $33.4M | $57.5M | |
| Total Liabilities | -- | -- | $23.4M | $36.4M | $62.1M | |
| Total Equity | -- | -- | $193M | $896.8M | $770M | |
| Total Debt | -- | -- | $3M | $2.7M | $4.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$69.8M | -$102.2M | -$194.5M | -$19.9M | -$51M | |
| Cash From Investing | -$77.3M | -$573.5M | $67.2M | -$189.8M | -$49.5M | |
| Cash From Financing | $169.6M | $797.2M | $57.9M | $512.9K | $56.3M | |
| Free Cash Flow | -$70.9M | -$104.6M | -$196.7M | -$20.6M | -$52.6M | |
GPCR
Sector
Market Cap
$4B
$28.5M
Price % of 52-Week High
73.74%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-3.66%
-1.33%
1-Year Price Total Return
109.84%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$38.22
200-day SMA
Buy
Level
$23.71
Bollinger Bands (100)
Buy
Level
18.11 - 33.75
Chaikin Money Flow
Sell
Level
-32.2M
20-day SMA
Buy
Level
$36.44
Relative Strength Index (RSI14)
Buy
Level
86.01
ADX Line
Buy
Level
32.76
Williams %R
Neutral
Level
-38.9619
50-day SMA
Buy
Level
$32.10
MACD (12, 26)
Buy
Level
3.48
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
42.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (24.2681)
Buy
CA Score
(Annual)
Level (0.5756)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.5648)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, GPCR has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GPCR average analyst price target in the past 3 months is $76.36.
-
Where Will Structure Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Structure Therapeutics, Inc. share price will rise to $76.36 per share over the next 12 months.
-
What Do Analysts Say About Structure Therapeutics, Inc.?
Analysts are divided on their view about Structure Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Structure Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $44.00.
-
What Is Structure Therapeutics, Inc.'s Price Target?
The price target for Structure Therapeutics, Inc. over the next 1-year time period is forecast to be $76.36 according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GPCR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Structure Therapeutics, Inc. is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GPCR?
You can purchase shares of Structure Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Structure Therapeutics, Inc. shares.
-
What Is The Structure Therapeutics, Inc. Share Price Today?
Structure Therapeutics, Inc. was last trading at $69.99 per share. This represents the most recent stock quote for Structure Therapeutics, Inc.. Yesterday, Structure Therapeutics, Inc. closed at $69.98 per share.
-
How To Buy Structure Therapeutics, Inc. Stock Online?
In order to purchase Structure Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GPCR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GPCR
Sector
P/E ratio
--
23.75x
PEG ratio
-0.30x
-0.01x
P/B ratio
5.23x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
GPCR
Sector
Revenue growth
--
4.85%
Earnings growth
-87.88%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.43
-$0.20
Profitability
GPCR
Sector
Profitability FY 2024
-$2.6M
$3.6M
Return on invested capital
-25.36%
-30.98%
Return on assets
-24.24%
-27.62%
Return on equity
-25.55%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
GPCR
Sector
Total cash
$799M
$27.2M
Short term investments
$714M
$25.7M
Total assets
$903.3M
$79.7M
Long term debt
$4.3M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
56
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is up 102.52% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
